Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

1.

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.

Nature.
Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK, Kim CF.
| Jan 28, 2015
2.

Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.

Proc. Natl. Acad. Sci. U.S.A.
Leshchiner ES, Parkhitko A, Bird GH, Luccarelli J, Bellairs JA, Escudero S, Opoku-Nsiah K, Godes M, Perrimon N, Walensky LD.
| Jan 26, 2015
3.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

Proc. Natl. Acad. Sci. U.S.A.
Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK.
| Jan 20, 2015
4.

Force-dependent transition in the T-cell receptor β-subunit allosterically regulates peptide discrimination and pMHC bond lifetime.

Proc. Natl. Acad. Sci. U.S.A.
Das DK, Feng Y, Mallis RJ, Li X, Keskin DB, Hussey RE, Brady SK, Wang JH, Wagner G, Reinherz EL, Lang MJ.
| Jan 20, 2015
5.

Hematopoietic stem cell arrival triggers dynamic remodeling of the perivascular niche.

Cell.
Tamplin OJ, Durand EM, Carr LA, Childs SJ, Hagedorn EJ, Li P, Yzaguirre AD, Speck NA, Zon LI.
| Jan 15, 2015
6.

Molecular and genetic properties of tumors associated with local immune cytolytic activity.

Cell.
Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N.
| Jan 15, 2015
7.

Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection.

Science.
Penaloza-MacMaster P, Barber DL, Wherry EJ, Provine NM, Teigler JE, Parenteau L, Blackmore S, Borducchi EN, Larocca RA, Yates KB, Shen H, Haining WN, Sommerstein R, Pinschewer DD, Ahmed R, Barouch DH.
| Jan 16, 2015
8.

Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.

Nat. Genet.
Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, Gulsuner S, Pritchard CC, Sanchez-Bonilla M, Delrow JJ, Basom RS, Forouhar M, Gyurkocza B, Schwartz BS, Neistadt B, Marquez R, Mariani CJ, Coats SA, Hofmann I, Lindsley RC, Williams DA, Abkowitz JL, Horwitz MS, King MC, Godley LA, Shimamura A.
| 01 12, 2015
9.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

N. Engl. J. Med.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.
| Jan 8, 2015
10.

Appearance and disappearance of the mRNA signature characteristic of Treg cells in visceral adipose tissue: Age, diet, and PPARγ effects.

Proc. Natl. Acad. Sci. U.S.A.
Cipolletta D, Cohen P, Spiegelman BM, Benoist C, Mathis D.
| Jan 13, 2015
11.

Intracellular osteopontin regulates homeostasis and function of natural killer cells.

Proc. Natl. Acad. Sci. U.S.A.
Leavenworth JW, Verbinnen B, Wang Q, Shen E, Cantor H.
| Jan 13, 2015
12.

Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation.

Proc. Natl. Acad. Sci. U.S.A.
Godec J, Cowley GS, Barnitz RA, Root DE, Sharpe AH, Haining WN.
| Jan 13, 2015
13.

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.

Proc. Natl. Acad. Sci. U.S.A.
Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, Beroukhim R, Bradner JE, Drapkin R, Hahn WC, Liu JF, Livingston DM.
| Jan 6, 2015
14.

Genetic modifiers of EGFR dependence in non-small cell lung cancer.

Proc. Natl. Acad. Sci. U.S.A.
Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M.
| Dec 30, 2014
15.

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

Proc. Natl. Acad. Sci. U.S.A.
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, Dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CW, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G, Janeway KA.
| Dec 23, 2014
16.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Proc. Natl. Acad. Sci. U.S.A.
Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD.
| Dec 30, 2014
17.

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

Proc. Natl. Acad. Sci. U.S.A.
He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N.
| Dec 23, 2014
18.

HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.

Proc. Natl. Acad. Sci. U.S.A.
Whitesell L, Santagata S, Mendillo ML, Lin NU, Proia DA, Lindquist S.
| Dec 23, 2014
19.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Nat. Med.
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.
| 12 08, 2014
20.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

N. Engl. J. Med.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P.
| Jan 22, 2015